ERBB2 and triple-negative breast carcinoma: Patients with breast cancers that do not express the ER, PR, and HER2, so-called triple-negative breast cancers (TNBCs), do not benefit from antihormonal or anti-HER2-targeted treatments, and rely on conventional chemotherapeutic regimens.